Focus: AMO Pharma is a private pharmaceutical company focused on rare and orphan diseases, headquartered in Durham, NC with a lean pipeline anchored on Tideglusib for myotonic dystrophy and related indications. The company operates in a specialized niche targeting underserved patient populations with significant unmet medical need.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
A high-risk/high-reward rare disease biotech suitable for mission-driven professionals comfortable with early-stage uncertainty but attracted to orphan indications and potential regulatory fast-tracks.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for AMO Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AMO Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles